BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 25301847)

  • 1. Reproducible, Quantitative, and Flexible Molecular Subtyping of Clinical DLBCL Samples Using the NanoString nCounter System.
    Veldman-Jones MH; Lai Z; Wappett M; Harbron CG; Barrett JC; Harrington EA; Thress KS
    Clin Cancer Res; 2015 May; 21(10):2367-78. PubMed ID: 25301847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. nCounter NanoString Assay Shows Variable Concordance With Immunohistochemistry-based Algorithms in Classifying Cases of Diffuse Large B-Cell Lymphoma According to the Cell-of-Origin.
    Saad AG; Grada Z; Bishop B; Abulsayen H; Hassan M; Firpo-Betancourt A; Teruya-Feldstein J; Fraig M; El Jamal SM
    Appl Immunohistochem Mol Morphol; 2019 Oct; 27(9):644-648. PubMed ID: 30179888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell-of-Origin Subtyping of Diffuse Large B-Cell Lymphoma by Using a qPCR-based Gene Expression Assay on Formalin-Fixed Paraffin-Embedded Tissues.
    Yan WH; Jiang XN; Wang WG; Sun YF; Wo YX; Luo ZZ; Xu QH; Zhou XY; Cao JN; Hong XN; Li XQ
    Front Oncol; 2020; 10():803. PubMed ID: 32582543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Subtyping of Diffuse Large B-Cell Lymphoma Using a Novel Quantitative RT-PCR Assay.
    Ta R; Santini C; Gou P; Lee G; Tai YC; O'Brien C; Fontecha M; Grant C; Bacon L; Finn S; Vandenberghe E; Quinn F; Dua R; Flavin R
    J Mol Diagn; 2021 Mar; 23(3):323-340. PubMed ID: 33385586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma.
    Zhou M; Zhao H; Xu W; Bao S; Cheng L; Sun J
    Mol Cancer; 2017 Jan; 16(1):16. PubMed ID: 28103885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of protein-based cell-of-origin classification to the Lymph2Cx RNA assay in a cohort of diffuse large B-cell lymphomas in Malaysia.
    Phang KC; Akhter A; Tizen NMS; Rahman FA; Zahratul Azma R; Elyamany G; Shabani-Rad MT; Masir N; Mansoor A
    J Clin Pathol; 2018 Mar; 71(3):215-220. PubMed ID: 28775174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffin-embedded tissues.
    Rimsza LM; Wright G; Schwartz M; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Cook JR; Tubbs RR; Braziel RM; Delabie J; Miller TP; Staudt LM
    Clin Cancer Res; 2011 Jun; 17(11):3727-32. PubMed ID: 21364035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platform independent protein-based cell-of-origin subtyping of diffuse large B-cell lymphoma in formalin-fixed paraffin-embedded tissue.
    Reinders J; Altenbuchinger M; Limm K; Schwarzfischer P; Scheidt T; Strasser L; Richter J; Szczepanowski M; Huber CG; Klapper W; Spang R; Oefner PJ
    Sci Rep; 2020 May; 10(1):7876. PubMed ID: 32398793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. QuantiGene Plex Represents a Promising Diagnostic Tool for Cell-of-Origin Subtyping of Diffuse Large B-Cell Lymphoma.
    Hall JS; Usher S; Byers RJ; Higgins RC; Memon D; Radford JA; Linton KM
    J Mol Diagn; 2015 Jul; 17(4):402-11. PubMed ID: 25982535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and validation of a two-gene expression index for subtype classification and prognosis in Diffuse Large B-Cell Lymphoma.
    Xu Q; Tan C; Ni S; Wang Q; Wu F; Liu F; Ye X; Meng X; Sheng W; Du X
    Sci Rep; 2015 May; 5():10006. PubMed ID: 25940947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell-of-Origin in Diffuse Large B-Cell Lymphoma: Are the Assays Ready for the Clinic?
    Scott DW
    Am Soc Clin Oncol Educ Book; 2015; ():e458-66. PubMed ID: 25993210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma.
    Wright G; Tan B; Rosenwald A; Hurt EH; Wiestner A; Staudt LM
    Proc Natl Acad Sci U S A; 2003 Aug; 100(17):9991-6. PubMed ID: 12900505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diffuse large B-cell lymphoma: sub-classification by massive parallel quantitative RT-PCR.
    Xue X; Zeng N; Gao Z; Du MQ
    Lab Invest; 2015 Jan; 95(1):113-20. PubMed ID: 25418578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microarray gene expression analysis of fixed archival tissue permits molecular classification and identification of potential therapeutic targets in diffuse large B-cell lymphoma.
    Linton K; Howarth C; Wappett M; Newton G; Lachel C; Iqbal J; Pepper S; Byers R; Chan WJ; Radford J
    J Mol Diagn; 2012; 14(3):223-32. PubMed ID: 22446084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of reverse transcriptase - Multiplex ligation-dependant probe amplification (RT-MLPA) in the molecular classification of Diffuse Large B cell lymphoma (DLBCL) by cell-of-origin (COO).
    Dcunha N; Sakhti D; Sigamani E; Chandramohan J; Korula A; George B; Manipadam MT; Pai R
    Indian J Pathol Microbiol; 2023; 66(4):714-719. PubMed ID: 38084521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
    Thieblemont C; Briere J; Mounier N; Voelker HU; Cuccuini W; Hirchaud E; Rosenwald A; Jack A; Sundstrom C; Cogliatti S; Trougouboff P; Boudova L; Ysebaert L; Soulier J; Chevalier C; Bron D; Schmitz N; Gaulard P; Houlgatte R; Gisselbrecht C
    J Clin Oncol; 2011 Nov; 29(31):4079-87. PubMed ID: 21947824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL.
    Xu-Monette ZY; Zhang H; Zhu F; Tzankov A; Bhagat G; Visco C; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; You H; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; van Krieken JH; Piris MA; Winter JN; Hagemeister FB; Shahbaba B; De Dios I; Zhang H; Li Y; Xu B; Albitar M; Young KH
    Blood Adv; 2020 Jul; 4(14):3391-3404. PubMed ID: 32722783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Refining diffuse large B-cell lymphoma subgroups using integrated analysis of molecular profiles.
    Dubois S; Tesson B; Mareschal S; Viailly PJ; Bohers E; Ruminy P; Etancelin P; Peyrouze P; Copie-Bergman C; Fabiani B; Petrella T; Jais JP; Haioun C; Salles G; Molina TJ; Leroy K; Tilly H; Jardin F;
    EBioMedicine; 2019 Oct; 48():58-69. PubMed ID: 31648986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue microarray in a subset of South African patients with DLBCL.
    Sissolak G; Wood L; Smith L; Chan JW; Armitage J; Jacobs P
    Transfus Apher Sci; 2013 Oct; 49(2):120-32. PubMed ID: 23942329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implications of the molecular subtypes of diffuse large B-cell lymphoma.
    Hill BT; Sweetenham J
    Leuk Lymphoma; 2012 May; 53(5):763-9. PubMed ID: 21992676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.